Fuzheng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fuzheng Zhang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Jianfeng Huang
Department of Radiation Oncology Affiliated Hospital of Jiangnan University Wuxi China
3 shared publications Qingfeng Pang
Department of Physiopathology, Wuxi Medical School of Jiangnan University, Wuxi 214122, Jiangsu Province, China
3 shared publicationsBo Yang
Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China,
2 shared publications- Bo Yang
Department of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, China; Wuxi Clinical Cancer Center, Wuxi, China
2 shared publications Danqi Qian
Department of Radiotherapy, The Affiliated Hospital of Jiangnan University, Binhu, Wuxi, Jiangsu 214062, P.R. China
2 shared publicationsErwen Bao
Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi 214062, Jiangsu Province, China
2 shared publications
Latest Publications
- 21 March 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 74 (00189456) , 1-12
High-Accuracy, Wide-Dynamic Range Continuous FBG Interrogator Based on an AWG
Although arrayed waveguide gratings (AWGs) are widely used in fiber Bragg grating (FBG) demodulation systems, their applications in real environments have been limited due to their narrow dynamic range and inability to continuously demodulate FBGs because of the finite bandwidth of AWG channels. Here, we developed a wide-dynamic-range, high-accuracy, continuous-demodulation FBG interrogator utilizing a dual-input channel on-chip silicon AWG. The introduction of two input channels in the AWG allowed two spectral peaks in each channel; therefore, staggered spectral peaks were realized. A joint-peak demodulation algorithm based on this spectrum is proposed to improve the dynamic range and demodulation accuracy. With the proposed structure and algorithm, we achieved continuous interrogation with a demodulation accuracy of 25.58 pm and a dynamic range of 24.5 nm in the 1537.5-1565.3 nm wavelength region. The relative demodulation accuracy within the full range reaches 0.1%. The dynamic range of adjacent channels is 5.4 nm, which is approximately 4 times greater than the dynamic range of an FBG conventional demodulation system using an AWG, and the relative demodulation accuracy is 0.47%. This developed interrogator, with a core size of 420 μm × 300 μm, theoretically explained and experimentally verified the possibility of the accurate measurement of an arbitrary FBG wavelength with high demodulation accuracy in the measurement range. This work achieved continuous monitoring of external temperature by FBGs and demonstrated their significant potential in expanding the application field of FBGs.
- 21 March 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 74 (00189456) , 1-12
High-Accuracy, Wide-Dynamic Range Continuous FBG Interrogator Based on an AWG
Although arrayed waveguide gratings (AWGs) are widely used in fiber Bragg grating (FBG) demodulation systems, their applications in real environments have been limited due to their narrow dynamic range and inability to continuously demodulate FBGs because of the finite bandwidth of AWG channels. Here, we developed a wide-dynamic-range, high-accuracy, continuous-demodulation FBG interrogator utilizing a dual-input channel on-chip silicon AWG. The introduction of two input channels in the AWG allowed two spectral peaks in each channel; therefore, staggered spectral peaks were realized. A joint-peak demodulation algorithm based on this spectrum is proposed to improve the dynamic range and demodulation accuracy. With the proposed structure and algorithm, we achieved continuous interrogation with a demodulation accuracy of 25.58 pm and a dynamic range of 24.5 nm in the 1537.5-1565.3 nm wavelength region. The relative demodulation accuracy within the full range reaches 0.1%. The dynamic range of adjacent channels is 5.4 nm, which is approximately 4 times greater than the dynamic range of an FBG conventional demodulation system using an AWG, and the relative demodulation accuracy is 0.47%. This developed interrogator, with a core size of 420 μm × 300 μm, theoretically explained and experimentally verified the possibility of the accurate measurement of an arbitrary FBG wavelength with high demodulation accuracy in the measurement range. This work achieved continuous monitoring of external temperature by FBGs and demonstrated their significant potential in expanding the application field of FBGs.
- 3 February 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 72 (00189456) , 1-13
An Active Contour Model Based on Local Pre-Piecewise Fitting Bias Corrections for Fast and Accurate Segmentation
The lack of grasp of the image information and the unstable fluctuation of the model energy may cause segmentation failure of the active contour model (ACM). Minimizing the impact of these two factors is critical. A local pre-piecewise fitting (LPPF) bias correction model for fast and accurate segmentation is proposed in this paper. It defines a pre-fitting function of local regions and an energy function. The grayscale information of small areas in the image is fully extracted, so that the contour accurately locates the target. Then, the optimal solution to the estimated value of the bias field is obtained. The real image information is described by the bias field, and the energy function of the model is constructed. The optimized distance regularized term and neighborhood average filtering method are utilized to achieve level set function regularization and contour smoothing. This optimization process reduces the amount of calculation and improves the robustness of LPPF model. Experiments are performed to verify that LPPF model has strong robustness to initial contours and has ability to segment blurry images while satisfactory segmentation efficiency and accuracy are obtained.
- 3 February 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 72 (00189456) , 1-13
An Active Contour Model Based on Local Pre-Piecewise Fitting Bias Corrections for Fast and Accurate Segmentation
The lack of grasp of the image information and the unstable fluctuation of the model energy may cause segmentation failure of the active contour model (ACM). Minimizing the impact of these two factors is critical. A local pre-piecewise fitting (LPPF) bias correction model for fast and accurate segmentation is proposed in this paper. It defines a pre-fitting function of local regions and an energy function. The grayscale information of small areas in the image is fully extracted, so that the contour accurately locates the target. Then, the optimal solution to the estimated value of the bias field is obtained. The real image information is described by the bias field, and the energy function of the model is constructed. The optimized distance regularized term and neighborhood average filtering method are utilized to achieve level set function regularization and contour smoothing. This optimization process reduces the amount of calculation and improves the robustness of LPPF model. Experiments are performed to verify that LPPF model has strong robustness to initial contours and has ability to segment blurry images while satisfactory segmentation efficiency and accuracy are obtained.
- 1 November 2021
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 40 (11) , 1428-1444
Predictive and Prognostic Value of an MicroRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy
Gastric carcinoma (GC) is one of the most common cause of tumor-related death. Chemotherapy resistance usually occurs, leading to cancer relapse and poor survival of GC patients. To investigate the role of miRNAs in chemotherapy resistance for GC patients, we conducted an integrated analysis of miRNA expression and survival information using data obtained from The Cancer Genome Atlas project. Genome-wide screening of chemotherapy response-specific miRNAs was performed using Cox proportional hazards regression analyses for patients who received chemotherapy or those who had never received chemotherapy, respectively. A four-miRNA expression signature (involving two protective miRNAs, miR-200b and miR-103a, and two risk ones miR-199 and miR-152) was predicted as a specific indicator for GC chemoresistance (p = 0.00053; hazard ratio = 8.63), outperforming those clinicopathological factors. Functional experiments confirmed the roles of these signature miRNAs in regulation of chemotherapy response. Functional enrichment of these signature miRNAs and risk score revealed positive association with epithelial-mesenchymal transition (EMT), and negative association with cell cycle checkpoint and DNA damage response. Furthermore, the immune infiltration-miRNA functional network analysis revealed transformation from activated effector cells to resting immunosuppressive cells are preferred in GCs with adverse chemotherapy response. In summary, our work identifies a four-miRNA expression signature as a promising chemoresistance biomarker in GC, which provides novel insights into developing new strategies to overcome GC chemoresistance.
- 1 November 2021
- Published by SAGE Publications in DNA and Cell Biology
- Vol. 40 (11) , 1428-1444
Predictive and Prognostic Value of an MicroRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy
Gastric carcinoma (GC) is one of the most common cause of tumor-related death. Chemotherapy resistance usually occurs, leading to cancer relapse and poor survival of GC patients. To investigate the role of miRNAs in chemotherapy resistance for GC patients, we conducted an integrated analysis of miRNA expression and survival information using data obtained from The Cancer Genome Atlas project. Genome-wide screening of chemotherapy response-specific miRNAs was performed using Cox proportional hazards regression analyses for patients who received chemotherapy or those who had never received chemotherapy, respectively. A four-miRNA expression signature (involving two protective miRNAs, miR-200b and miR-103a, and two risk ones miR-199 and miR-152) was predicted as a specific indicator for GC chemoresistance (p = 0.00053; hazard ratio = 8.63), outperforming those clinicopathological factors. Functional experiments confirmed the roles of these signature miRNAs in regulation of chemotherapy response. Functional enrichment of these signature miRNAs and risk score revealed positive association with epithelial-mesenchymal transition (EMT), and negative association with cell cycle checkpoint and DNA damage response. Furthermore, the immune infiltration-miRNA functional network analysis revealed transformation from activated effector cells to resting immunosuppressive cells are preferred in GCs with adverse chemotherapy response. In summary, our work identifies a four-miRNA expression signature as a promising chemoresistance biomarker in GC, which provides novel insights into developing new strategies to overcome GC chemoresistance.
- Open Access
- 11 February 2021
- Published by Impact Journals, LLC in Aging
- Vol. 13 (4) , 5674-5685
High expression of heme oxygenase-1 in tumor-associated macrophages characterizes a poor-prognosis subtype in nasopharyngeal carcinoma
Tumor-associated macrophages (TAMs) are important components of the tumor microenvironment, which are characterized by pro-tumor M2 phenotype and correlate with poor survival of nasopharyngeal carcinoma (NPC). Heme oxygenase-1 (HO-1) plays a crucial role in macrophage polarization toward M2 phenotype, but its prognosis significance in NPC has been rarely determined. To gain insights into the HO-1 expression profile and to determine the clinical significance of HO-1 in NPC, we performed immunohistochemistry analyses in 126 NPC specimens. CD163, a highly specific marker of M2 macrophages, was used as a surrogate for the polarization state of TAMs. Our results showed that high expression of HO-1 and CD163 were detected in TAMs for 57.9% (73/126) and 61.9% (78/126) of the studied patients, and both of them were significantly associated with worse survival. Additionally, a significant correlation between the intensities of HO-1 and CD163 was identified, and HO-1 exhibited a superior ability in predicting survival compared with CD163. Our study revealed for the first time that overexpression of HO-1 characterized a poor-prognosis subtype in NPC. Individualized therapy targeting HO-1 might serve as a promising treatment modality for NPC.
- 11 February 2021
- Published by Impact Journals, LLC in Aging
- Vol. 13 (4) , 5674-5685
Open AccessHigh expression of heme oxygenase-1 in tumor-associated macrophages characterizes a poor-prognosis subtype in nasopharyngeal carcinoma
Tumor-associated macrophages (TAMs) are important components of the tumor microenvironment, which are characterized by pro-tumor M2 phenotype and correlate with poor survival of nasopharyngeal carcinoma (NPC). Heme oxygenase-1 (HO-1) plays a crucial role in macrophage polarization toward M2 phenotype, but its prognosis significance in NPC has been rarely determined. To gain insights into the HO-1 expression profile and to determine the clinical significance of HO-1 in NPC, we performed immunohistochemistry analyses in 126 NPC specimens. CD163, a highly specific marker of M2 macrophages, was used as a surrogate for the polarization state of TAMs. Our results showed that high expression of HO-1 and CD163 were detected in TAMs for 57.9% (73/126) and 61.9% (78/126) of the studied patients, and both of them were significantly associated with worse survival. Additionally, a significant correlation between the intensities of HO-1 and CD163 was identified, and HO-1 exhibited a superior ability in predicting survival compared with CD163. Our study revealed for the first time that overexpression of HO-1 characterized a poor-prognosis subtype in NPC. Individualized therapy targeting HO-1 might serve as a promising treatment modality for NPC.
- Open Access
- 4 September 2020
- Published by Springer Nature in Research Square
Predictive and Prognostic Value of an microRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy
PurposeGastric carcinoma (GC) is one of the most common cause of tumor-related death. Chemotherapy resistance usually occurs, leading to cancer relapse and poor survival of GC patients. To investigate the role of miRNAs in chemotherapy resistance for GC patients, we conducted an integrated analysis of miRNA expression and survival information using data obtained from the TCGA project. Materials and methodsGenome-wide screening of chemotherapy response-specific miRNAs was performed using Cox proportional hazards regression analyses for patients received chemotherapy or those had never received chemotherapy, respectively. CCK-8 assay was used for assessing cell viability. GSEA and single sample GSVA were performed for functional enrichment analysis. CIBERSORT cellular composition analysis was used to infer immune cell populations in GC tumors.ResultsA four-miRNA expression signature involving miR-130, -152, -199 and -200b was predicted as a specific indicator for GC chemoresistance (P = 0.00053; hazard ratio = 8.63), outperforming those clinicopathological factors. Functional experiments confirmed the roles of these signature miRNAs in regulation of chemotherapy response. Functional enrichment of these signature miRNAs and risk score revealed positive association with epithelial-mesenchymal transition (EMT), and negative association with cell cycle checkpoint and DNA damage response. Furthermore, the immune infiltration-miRNA functional network analysis revealed transformation from activated effector cells to resting immunosuppressive cells are preferred in GCs with adverse chemotherapy response.ConclusionsOur work identifies a four‑miRNA expression signature as a promising chemoresistance biomarker in gastric carcinoma, which provides novel insights into developing new strategies to overcome GC chemoresistance.
- 4 September 2020
- Published by Springer Nature in Research Square
Open AccessPredictive and Prognostic Value of an microRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy
PurposeGastric carcinoma (GC) is one of the most common cause of tumor-related death. Chemotherapy resistance usually occurs, leading to cancer relapse and poor survival of GC patients. To investigate the role of miRNAs in chemotherapy resistance for GC patients, we conducted an integrated analysis of miRNA expression and survival information using data obtained from the TCGA project. Materials and methodsGenome-wide screening of chemotherapy response-specific miRNAs was performed using Cox proportional hazards regression analyses for patients received chemotherapy or those had never received chemotherapy, respectively. CCK-8 assay was used for assessing cell viability. GSEA and single sample GSVA were performed for functional enrichment analysis. CIBERSORT cellular composition analysis was used to infer immune cell populations in GC tumors.ResultsA four-miRNA expression signature involving miR-130, -152, -199 and -200b was predicted as a specific indicator for GC chemoresistance (P = 0.00053; hazard ratio = 8.63), outperforming those clinicopathological factors. Functional experiments confirmed the roles of these signature miRNAs in regulation of chemotherapy response. Functional enrichment of these signature miRNAs and risk score revealed positive association with epithelial-mesenchymal transition (EMT), and negative association with cell cycle checkpoint and DNA damage response. Furthermore, the immune infiltration-miRNA functional network analysis revealed transformation from activated effector cells to resting immunosuppressive cells are preferred in GCs with adverse chemotherapy response.ConclusionsOur work identifies a four‑miRNA expression signature as a promising chemoresistance biomarker in gastric carcinoma, which provides novel insights into developing new strategies to overcome GC chemoresistance.
- Open Access
- 3 March 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 19 (4) , 3229-3238
Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer
Real‑time assessment of therapeutic response in patients with advanced lung cancer presents a major challenge throughout the treatment process. Currently, computed tomography imaging is often used; however, it is radiation‑based and hysteretic and is not suitable for repeated use as a real‑time assessment. Blood biomarkers represent a novel solution for assessing therapeutic response in patients with advanced lung cancer. In the present study, the efficacy of a methylation marker [methylated prostaglandin E receptor 4 (mPTGER4)] and four protein markers [carcinoma antigen 125 (CA125), carcinoembryonic antigen (CEA), cytokeratin 19‑fragments (cyfra21‑1) and neuron‑specific enolase (NSE)] were simultaneously evaluated to determine their potential in facilitating therapeutic response monitoring as well as their prognostic values in patients with stage IV lung cancer. The results indicated that, following treatment, the blood levels of methylated PTGER4 and NSE had significantly decreased, and mPRGER4, CA125, CEA and NSE exhibited a significant decrease in percentage level. Since mPTGER4 exhibited a higher rate of positive detection prior to therapy, and a greater response of sensitivity to therapy compared to the protein markers, it may represent an improved marker for the monitoring of therapeutic response. The efficacy of the markers in predicting the overall survival (OS) rate of patients with stage IV lung cancer was also assessed. Results from the follow‑up of patients (up to 891 days) revealed that the blood levels of mPTGER4, CA125 and NSE before treatment were able to predict overall survival (OS) rate. Additionally, the percentage change in expression levels of CA125, CEA and NSE was also able to predict the OS rate. In conclusion, the present results indicate that mPTGER4 represents an improved biomarker for monitoring therapeutic efficacy compared with CA125, CEA, Cyfra21‑1 and NSE. In predicting the long‑term survival of patients with stage IV lung cancer; however, the pre‑treatment levels of mPTGER4, CA125 and NSE and the percentage changes of CA125, CEA and NSE may be used as the markers.
- 3 March 2020
- Published by Spandidos Publications in Oncology Letters
- Vol. 19 (4) , 3229-3238
Open AccessMethylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer
Real‑time assessment of therapeutic response in patients with advanced lung cancer presents a major challenge throughout the treatment process. Currently, computed tomography imaging is often used; however, it is radiation‑based and hysteretic and is not suitable for repeated use as a real‑time assessment. Blood biomarkers represent a novel solution for assessing therapeutic response in patients with advanced lung cancer. In the present study, the efficacy of a methylation marker [methylated prostaglandin E receptor 4 (mPTGER4)] and four protein markers [carcinoma antigen 125 (CA125), carcinoembryonic antigen (CEA), cytokeratin 19‑fragments (cyfra21‑1) and neuron‑specific enolase (NSE)] were simultaneously evaluated to determine their potential in facilitating therapeutic response monitoring as well as their prognostic values in patients with stage IV lung cancer. The results indicated that, following treatment, the blood levels of methylated PTGER4 and NSE had significantly decreased, and mPRGER4, CA125, CEA and NSE exhibited a significant decrease in percentage level. Since mPTGER4 exhibited a higher rate of positive detection prior to therapy, and a greater response of sensitivity to therapy compared to the protein markers, it may represent an improved marker for the monitoring of therapeutic response. The efficacy of the markers in predicting the overall survival (OS) rate of patients with stage IV lung cancer was also assessed. Results from the follow‑up of patients (up to 891 days) revealed that the blood levels of mPTGER4, CA125 and NSE before treatment were able to predict overall survival (OS) rate. Additionally, the percentage change in expression levels of CA125, CEA and NSE was also able to predict the OS rate. In conclusion, the present results indicate that mPTGER4 represents an improved biomarker for monitoring therapeutic efficacy compared with CA125, CEA, Cyfra21‑1 and NSE. In predicting the long‑term survival of patients with stage IV lung cancer; however, the pre‑treatment levels of mPTGER4, CA125 and NSE and the percentage changes of CA125, CEA and NSE may be used as the markers.
- Open Access
- 1 October 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 8379-8386
Systematic nutrition management for locally advanced nasopharyngeal carcinoma patients undergoing radiotherapy
Objective: To evaluate the impact of systematic nutrition management (SNM) on nutritional status, treatment-related toxicity, quality of life (QoL), response rates, and survival in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) treated by radiotherapy (RT). Methods: In this retrospective study, 56 patients with LA-NPC were selected as nutrition management group (NG) for SNM during RT till 1 month later. Another 56 patients with LA-NPC receiving RT without SNM as control group (CG) were identified from the hospital database and matched pairs with NG patients according to age, gender, stage, and body mass index (BMI) prior to RT. Results: At 1 month after RT, the percentage of malnourished patients with BMI 2 was statistically significant reduced in NG as compared to the CG group (35.7% vs 58.9%, P=0.014). Nutritional indexes of body weight, hemoglobin, prealbumin, and lymphocyte in the NG were statistically significant higher than those in the CG group (P0.05) for the 2-year progression-free survival and overall survival (84.2% versus 79.5% and 94.7% versus 92.3%, respectively.). Conclusion: SNM for LA-NPC patients treated by RT resulted in better nutritional status, reduced treatment-related toxicity and improved QoL.
- 1 October 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 8379-8386
Open AccessSystematic nutrition management for locally advanced nasopharyngeal carcinoma patients undergoing radiotherapy
Objective: To evaluate the impact of systematic nutrition management (SNM) on nutritional status, treatment-related toxicity, quality of life (QoL), response rates, and survival in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) treated by radiotherapy (RT). Methods: In this retrospective study, 56 patients with LA-NPC were selected as nutrition management group (NG) for SNM during RT till 1 month later. Another 56 patients with LA-NPC receiving RT without SNM as control group (CG) were identified from the hospital database and matched pairs with NG patients according to age, gender, stage, and body mass index (BMI) prior to RT. Results: At 1 month after RT, the percentage of malnourished patients with BMI 2 was statistically significant reduced in NG as compared to the CG group (35.7% vs 58.9%, P=0.014). Nutritional indexes of body weight, hemoglobin, prealbumin, and lymphocyte in the NG were statistically significant higher than those in the CG group (P0.05) for the 2-year progression-free survival and overall survival (84.2% versus 79.5% and 94.7% versus 92.3%, respectively.). Conclusion: SNM for LA-NPC patients treated by RT resulted in better nutritional status, reduced treatment-related toxicity and improved QoL.
- Open Access
- 2 August 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (4) , 5020-5026
Liriodenine enhances radiosensitivity in esophageal cancer ECA‑109 cells by inducing apoptosis and G2/M arrest
At present, chemotherapy and radiotherapy represent the primary modalities of treatment for patients with unresectable esophageal squamous cell carcinoma (ESCC). However, the outcome of patients remains poor owing to radioresistance. The present study aimed to determine the radiosensitizing effect of liriodenine, an aporphine alkaloid derived from Enicosanthellum pulchrum, and investigating the underlying mechanisms in ESCC, using the esophageal cancer ECA‑109 cell line. Cellular proliferation was evaluated using the Cell Counting kit‑8 assay. Colony formation assay was performed to characterize the radiosensitive effects of liriodenine on ECA‑109 cells, and flow cytometry was used to detect the percentage of cells undergoing apoptosis. An immunofluorescence assay was utilized to evaluate the DNA damage repair ability. Western blotting was used to assess the protein levels of caspase‑3, B cell lymphoma‑2 (Bcl‑2) and Bcl‑2‑associated X (Bax). Liriodenine dose‑dependently inhibited ECA‑109 cell viability. The clonogenic survival assay demonstrated that liriodenine increased the radiosensitivity of ESCC cells, with a sensitization enhancement ratio of 1.11‑1.69. The results of flow cytometry demonstrated that liriodenine induced apoptosis and G2/M arrest. The immunofluorescence assay revealed that liriodenine delays DNA damage repair. The upregulation of Bax and Caspase‑3, and the suppression of Bcl‑2 confirmed that apoptosis was occurring. Liriodenine radiosensitizes ECA‑109 cells by inducing apoptosis and G2/M arrest. The findings of the present study indicated that liriodenine may represent an anticancer agent with promising potential for the treatment of ESCC.
- 2 August 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 16 (4) , 5020-5026
Open AccessLiriodenine enhances radiosensitivity in esophageal cancer ECA‑109 cells by inducing apoptosis and G2/M arrest
At present, chemotherapy and radiotherapy represent the primary modalities of treatment for patients with unresectable esophageal squamous cell carcinoma (ESCC). However, the outcome of patients remains poor owing to radioresistance. The present study aimed to determine the radiosensitizing effect of liriodenine, an aporphine alkaloid derived from Enicosanthellum pulchrum, and investigating the underlying mechanisms in ESCC, using the esophageal cancer ECA‑109 cell line. Cellular proliferation was evaluated using the Cell Counting kit‑8 assay. Colony formation assay was performed to characterize the radiosensitive effects of liriodenine on ECA‑109 cells, and flow cytometry was used to detect the percentage of cells undergoing apoptosis. An immunofluorescence assay was utilized to evaluate the DNA damage repair ability. Western blotting was used to assess the protein levels of caspase‑3, B cell lymphoma‑2 (Bcl‑2) and Bcl‑2‑associated X (Bax). Liriodenine dose‑dependently inhibited ECA‑109 cell viability. The clonogenic survival assay demonstrated that liriodenine increased the radiosensitivity of ESCC cells, with a sensitization enhancement ratio of 1.11‑1.69. The results of flow cytometry demonstrated that liriodenine induced apoptosis and G2/M arrest. The immunofluorescence assay revealed that liriodenine delays DNA damage repair. The upregulation of Bax and Caspase‑3, and the suppression of Bcl‑2 confirmed that apoptosis was occurring. Liriodenine radiosensitizes ECA‑109 cells by inducing apoptosis and G2/M arrest. The findings of the present study indicated that liriodenine may represent an anticancer agent with promising potential for the treatment of ESCC.
- RetractedOpen Access
- 1 July 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2223-2231
Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
Introduction: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. Materials and methods: 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide and clonogenic survival assays were done to evaluate the combined cytotoxic and radiosensitizing effects of nimotuzumab or celecoxib or the combination on CNE1 and CNE2 cells. Western blot analysis was performed to identify the effect of nimotuzumab and/or celecoxib with or without irradiation on the cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. Results: Our results demonstrated that concurrent administration of nimotuzumab and celecoxib cooperatively enhanced the cytotoxicity and radiosensitivity of CNE2 cells but not CNE1 cells. The combination of both drugs with or without irradiation also cooperatively inhibited cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. Conclusion: Our results suggest a promising approach for the treatment of poorly differentiated NPC.
- 1 July 2018
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 12, 2223-2231
RetractedOpen AccessRadiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
Introduction: In this study, the radiation-enhancing effects of combined treatment with nimotuzumab, a humanized EGFR-blocking antibody, and celecoxib, a COX-2 selective inhibitor, in human nasopharyngeal carcinoma (NPC) cells were investigated. Materials and methods: 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide and clonogenic survival assays were done to evaluate the combined cytotoxic and radiosensitizing effects of nimotuzumab or celecoxib or the combination on CNE1 and CNE2 cells. Western blot analysis was performed to identify the effect of nimotuzumab and/or celecoxib with or without irradiation on the cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. Results: Our results demonstrated that concurrent administration of nimotuzumab and celecoxib cooperatively enhanced the cytotoxicity and radiosensitivity of CNE2 cells but not CNE1 cells. The combination of both drugs with or without irradiation also cooperatively inhibited cytoplasmic and nuclear EGFR signaling pathways in CNE2 cells. Conclusion: Our results suggest a promising approach for the treatment of poorly differentiated NPC.
- Open Access
- 1 December 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 5835-5841
Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma
Objective: This study aimed to evaluate the safety and efficacy of intensity-modulated radiotherapy (IMRT) plus nimotuzumab with or without concurrent chemotherapy (CCT) for patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Patients and methods: A total of 50 newly diagnosed patients with LA-NPC treated at the Affiliated Hospital of Jiangnan University between November 2011 and January 2017 were retrospectively analyzed. All patients received the combined treatment modality of nimotuzumab plus IMRT. Nimotuzumab was administered concurrently with IMRT at a weekly dose of 200 mg. Neoadjuvant, concurrent or adjuvant chemotherapy with the doublet regimen of taxanes (docetaxel or paclitaxel) plus platinum (cisplatin or nedaplatin) were administered. Among the 50 patients, 43 (86.0%) received ≥6 cycles of nimotuzumab (median 7 cycles, range 2–14 cycles) and 29 (58.0%) received two cycles of CCT with docetaxel plus nedaplatin. Results: With a median follow-up of 28.0 months, the 2-year progression-free survival (PFS) and overall survival were 83.29% (95% confidence interval [CI]: 67.93%–91.72%) and 97.67% (95% CI: 84.62%–99.67%), respectively. Both univariate and multivariate analyses revealed that cycles of nimotuzumab were significantly associated with PFS. Patients who received ≥6 cycles of nimotuzumab showed a better PFS than those receiving P=0.006), whereas the addition of CCT failed to improve PFS. Oral mucositis was the most common adverse event, which was recorded as grade 3–4 in 18 (36.0%) patients. Besides, two (4.0%) patients experienced nimotuzumab-related anaphylaxis, and no skin rash was found in any patient. Subgroup analysis revealed that the patients who received CCT had more grade 3–4 adverse events as compared to those who did not receive CCT (62.1% vs 33.3%, P=0.045). Conclusion: The regime of nimotuzumab plus IMRT for the treatment of LA-NPC was well tolerated, with encouraging survival data, and it could be an effective treatment alternative for patients with LA-NPC. Further clinical trials are needed to confirm these findings.
- 1 December 2017
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 5835-5841
Open AccessIntensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma
Objective: This study aimed to evaluate the safety and efficacy of intensity-modulated radiotherapy (IMRT) plus nimotuzumab with or without concurrent chemotherapy (CCT) for patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Patients and methods: A total of 50 newly diagnosed patients with LA-NPC treated at the Affiliated Hospital of Jiangnan University between November 2011 and January 2017 were retrospectively analyzed. All patients received the combined treatment modality of nimotuzumab plus IMRT. Nimotuzumab was administered concurrently with IMRT at a weekly dose of 200 mg. Neoadjuvant, concurrent or adjuvant chemotherapy with the doublet regimen of taxanes (docetaxel or paclitaxel) plus platinum (cisplatin or nedaplatin) were administered. Among the 50 patients, 43 (86.0%) received ≥6 cycles of nimotuzumab (median 7 cycles, range 2–14 cycles) and 29 (58.0%) received two cycles of CCT with docetaxel plus nedaplatin. Results: With a median follow-up of 28.0 months, the 2-year progression-free survival (PFS) and overall survival were 83.29% (95% confidence interval [CI]: 67.93%–91.72%) and 97.67% (95% CI: 84.62%–99.67%), respectively. Both univariate and multivariate analyses revealed that cycles of nimotuzumab were significantly associated with PFS. Patients who received ≥6 cycles of nimotuzumab showed a better PFS than those receiving P=0.006), whereas the addition of CCT failed to improve PFS. Oral mucositis was the most common adverse event, which was recorded as grade 3–4 in 18 (36.0%) patients. Besides, two (4.0%) patients experienced nimotuzumab-related anaphylaxis, and no skin rash was found in any patient. Subgroup analysis revealed that the patients who received CCT had more grade 3–4 adverse events as compared to those who did not receive CCT (62.1% vs 33.3%, P=0.045). Conclusion: The regime of nimotuzumab plus IMRT for the treatment of LA-NPC was well tolerated, with encouraging survival data, and it could be an effective treatment alternative for patients with LA-NPC. Further clinical trials are needed to confirm these findings.